Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 8/20 | 0.40 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.40 |
| ▸ | RAD52 | P43351 | 2/20 | 0.39 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 3/20 | 0.38 |
| ▸ | TNK2 | Q07912 | 2/20 | 0.38 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | HTR7 | P34969 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
| ▸ | HTR6 | P50406 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29566942 | 1.00 | BRD4 (0.40) | BRD4IRAK4RAD52MAP4K1EGFR | |
| SCHEMBL29566947 | 0.92 | BRD4 (0.37) | BRD4IRAK4RAD52MAP4K1EGFR | |
| SCHEMBL24309442 | 0.92 | BRD4 (0.37) | BRD4IRAK4RAD52MAP4K1EGFR | |
| SCHEMBL24310005 | 0.92 | BRD4 (0.37) | BRD4IRAK4RAD52MAP4K1EGFR | |
| SCHEMBL29567224 | 0.92 | BRD4 (0.37) | BRD4IRAK4RAD52MAP4K1EGFR | |
| SCHEMBL24309946 | 0.88 | MAP4K1 (0.38) | BRD4IRAK4RAD52MAP4K1TNK2 | |
| SCHEMBL29566886 | 0.88 | PLK1 (0.40) | BRD4IRAK4RAD52MAP4K1TNK2 | |
| SCHEMBL26651248 | 0.88 | PLK1 (0.40) | BRD4IRAK4RAD52MAP4K1TNK2 | |
| SCHEMBL24310014 | 0.88 | HTR1A (0.42) | BRD4IRAK4RAD52MAP4K1TNK2 | |
| SCHEMBL24310343 | 0.88 | MAP4K1 (0.43) | BRD4RAD52MAP4K1PTK2HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS, SAN DIEGO | 2023-11-23 | — | — | US | disclosed |
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS, SAN DIEGO | 2023-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | BRD4 1716/4885IRAK4 1601/4885RAD52 4705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.